SRZN Earnings Date: Nov 6, 2026 (Estimated) — Surrozen, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is SRZN's next earnings date?
Surrozen, Inc. (SRZN) is expected to report Q3 2026 earnings on Friday, November 6, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.10 on revenue of $475,000.
How did SRZN do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Surrozen, Inc. posted EPS of -$0.41 versus the -$1.29 estimate, a beat of 68.0%. Revenue was $5.0M against a $467,250 estimate. The stock's 1-day post-earnings move was +18.4%.
How much does SRZN stock move after earnings?
SRZN beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.5% (up or down) in the day after earnings.
About Surrozen, Inc.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -1.29 | -0.41 | +67.97% | $5.0M | ✅ Beat | +18.39% | +9.66% | +5.18% |
| 2026-05-06 | Q1 2026 | -0.85 | -11.65 | -1270.59% | $5.0M | ❌ Miss | -9.90% | -11.69% | -36.95% |
| 2026-03-23 | Q4 2025 | -1.30 | -20.13 | -1448.46% | $500,000 | ❌ Miss | -0.95% | +8.76% | +30.86% |
| 2025-11-07 | Q3 2025 | -1.17 | -8.36 | -614.53% | $983,000 | ❌ Miss | -3.28% | +6.39% | +81.15% |
| 2025-08-08 | Q2 2025 | -1.23 | 2.55 | +307.32% | $983,000 | ✅ Beat | +4.45% | +16.53% | +22.44% |
| 2025-03-31 | Q4 2024 | -2.64 | -9.10 | -244.70% | $0 | ❌ Miss | -4.63% | -15.95% | -5.57% |
| 2024-08-12 | Q2 2024 | -2.79 | -7.99 | -186.38% | $0 | ❌ Miss | -10.14% | +6.85% | +14.93% |
| 2024-05-08 | Q1 2024 | -4.25 | -4.24 | +0.24% | $0 | ✅ Beat | +0.29% | -0.47% | +8.73% |
Showing last 8 quarters.